...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Stem Cells >Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines.
【24h】

Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines.

机译：树突状细胞和新佐剂在开发治疗性疫苗方面的应用进展。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The recent advances in immunology and biotechnology have opened new perspectives for the development of immunotherapy strategies against cancer and infectious diseases. The understanding of the pivotal role of dendritic cells in the initiation and regulation of the immune response has led to an ensemble of preclinical studies and pilot clinical trials, which have provided some evidence on the potential advantages of using dendritic cells as cellular adjuvants for the development of therapeutic vaccines against infectious diseases and malignancies. Current research efforts are focused on the definition of optimal protocols for dendritic cell-based therapies in patients. An additional area of emerging importance in the field of immunotherapy is the identification of safe, selective, and more powerful adjuvants, capable not only of enhancing immune protection against pathogens, but also of breaking tolerance against certain tumor-associated antigens, which is the critical issue for the development of cancer vaccines. The recent recognition of the key role of certain cytokines, such as type I interferons, in linking the innate and adaptive immunity through their action on dendritic cells opens new perspectives for using these natural factors as adjuvants for the development of therapeutic vaccines. We review some of the emerging research aspects in immunotherapy, with special attention to the perspectives of using new adjuvants and dendritic cell-based vaccines for the treatment of cancer and infectious diseases.
机译：免疫学和生物技术的最新进展为开发针对癌症和传染病的免疫疗法策略开辟了新的前景。对树突状细胞在免疫应答的启动和调节中的关键作用的理解导致了一系列临床前研究和中试临床试验，这些研究为使用树突状细胞作为细胞佐剂促进发展提供了一些证据治疗传染性疾病和恶性肿瘤的疫苗。当前的研究工作集中于对患者基于树突状细胞疗法的最佳治疗方案的定义。免疫治疗领域另一个新出现的重要领域是鉴定安全，选择性和功能更强的佐剂，这些佐剂不仅能够增强对病原体的免疫保护，而且能够打破对某些肿瘤相关抗原的耐受性，这一点至关重要开发癌症疫苗的问题。最近认识到某些细胞因子（例如I型干扰素）通过其对树突状细胞的作用将先天免疫和适应性免疫联系起来的关键作用，为使用这些天然因子作为佐剂开发治疗性疫苗开辟了新的前景。我们回顾了免疫疗法中一些新兴的研究领域，特别关注了使用新的佐剂和基于树突状细胞的疫苗治疗癌症和传染病的观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号